Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SciVision Biotech Inc. (1786.TW)
Kaohsiung, TW
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was founded in 1990 and is based in Kaohsiung, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.14% | +11.94% | -5.36% | -20.53% | -21.05% | -17.36% | -37.24% | -14.53% | +30.21% | +33.63% | +23.61% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Specialty Business Services: +7.6%+0.4% Q1'26: +0.5% (vs Q1'25)
-
EPS growth Specialty Business Services: +24.4%-32.1% Q1'26: -62.3% (vs Q1'25)
-
FCF margin FCF growth · Specialty Business Services: +27.6%+4.8% Q1'26: +19.0% (vs Q1'25)
-
EBIT margin Specialty Business Services: +9.0%+21.4% ★ Q1'26: +10.4% (vs Q1'25)
-
ROIC Specialty Business Services: +7.8%+11.8% ★ Q1'26: +4.2% (vs Q1'25)
-
Share dilution Specialty Business Services: +0.4%-2.7% ★ Q1'26: +1.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Specialty Business Services: -0.21×1.79× ★ Q1'26: 2.77× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|
| Revenue |
437.87M
est: 436.00M (+0.4%)
|
466.88M
est: 436.00M (+7.1%)
|
505.54M
est: 563.00M (-10.2%)
|
712.99M
est: 713.00M (0.0%)
|
883.31M
est: 883.00M (+0.0%)
|
886.62M
est: 1.03B (-14.2%)
|
| EBITDA |
155.18M
est: 171.15M (-9.3%)
|
177.21M
est: 171.15M (+3.5%)
|
177.27M
est: 221.00M (-19.8%)
|
281.35M
est: 279.89M (+0.5%)
|
362.50M
est: 333.44M (+8.7%)
|
270.35M
est: 390.08M (-30.7%)
|
| EBIT |
134.19M
est: 135.28M (-0.8%)
|
159.96M
est: 135.28M (+18.2%)
|
124.12M
est: 174.68M (-28.9%)
|
218.22M
est: 221.22M (-1.4%)
|
297.27M
est: 250.53M (+18.7%)
|
189.92M
est: 293.09M (-35.2%)
|
| Net Income |
120.70M
est: 89.04M (+35.6%)
|
128.01M
est: 136.62M (-6.3%)
|
101.72M
est: 141.39M (-28.1%)
|
177.90M
est: 198.09M (-10.2%)
|
242.25M
est: 274.67M (-11.8%)
|
162.34M
est: 380.48M (-57.3%)
|
| SGA |
128.02M
est: 147.00M (-12.9%)
|
136.87M
est: 147.00M (-6.9%)
|
153.95M
est: 189.82M (-18.9%)
|
259.44M
est: 240.40M (+7.9%)
|
346.86M
est: 312.41M (+11.0%)
|
333.67M
est: 365.48M (-8.7%)
|
| EPS |
1.84
est: 1.20 (+53.9%)
|
1.93
est: 1.83 (+5.2%)
|
1.54
est: 1.90 (-18.9%)
|
2.66
est: 2.66 (+0.0%)
|
3.51
est: 3.79 (-7.4%)
|
2.24
est: 5.25 (-57.3%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 76.2K | 0.65% |
| 2 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.01% | 183.2K | 0.58% |
| 3 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.01% | 4.2K | 0.54% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 40.5K | 0.46% |
| 5 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 184.6K | 0.07% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 95.1K | 0.39% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 82.6K | 0.29% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 22.8K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ru Ling Guo | Deputy GM, Vice President, Financial Officer & Accounting Officer and Director | — | female |
| Tai Xian Han | General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1786.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
